OmniComm Systems has announced that a major West coast biopharmaceutical company has selected OmniComm to provide eClinical solutions for two of its phase I HIV studies. Both HIV studies, involving over 100 patients, are expected to run for approximately seven months. OmniComm Systems has completed extensive work with this client in different therapeutic areas.
Stephen Johnson, COO of OmniComm, said: This latest contract, awarded to us by a major Biotech company reemphasizes the high value of the overall service offerings we bring to our clients. Our continued ability to provide uniquely tailored state of the art e-clinical solutions to life science companies is what distinguishes us from other EDC providers. Our products allow companies involved in clinical research, to stay competitive in the current healthcare market while significantly improving their operational efficiencies.
We will continue to add products and services to our mix to not only optimize the value to our customers, but to also generate additional revenue and increase shareholder value, he added.
Content from our partners
